Enliven Therapeutics (ELVN) Enterprise Value (2019 - 2026)

Enliven Therapeutics has disclosed Enterprise Value across 8 years of filings, most recently posting -$452.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$452.4 million, down 56.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$452.4 million (down 56.24% YoY), and the FY2025 annual result was -$462.6 million, down 272.57% from the prior year.
• Enterprise Value came in at -$452.4 million for Q1 2026 at Enliven Therapeutics, up from -$462.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$75.5 million in Q4 2022 to a low of -$490.5 million in Q2 2025.
• The 5-year median for Enterprise Value is -$253.1 million (2023), against an average of -$232.5 million.
• Across the five-year window, Enterprise Value surged 65.12% in 2024 and plunged 406.06% in 2025, its largest moves.
• Enliven Therapeutics' Enterprise Value stood at -$75.5 million in 2022, then plunged by 235.14% to -$253.1 million in 2023, then surged by 50.95% to -$124.2 million in 2024, then sank by 272.57% to -$462.6 million in 2025, then advanced by 2.21% to -$452.4 million in 2026.
• The last three Enterprise Value figures came in at -$452.4 million (Q1 2026), -$462.6 million (Q4 2025), and -$101.7 million (Q3 2025), per Business Quant data.